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Abstract: Ciliary neurotrophic factor (CNTF) is one of the most studied neuroprotective agents with 
acknowledged potential in treating diseases of the posterior eye segment. Although its efficacy and 
mechanisms of action in the retina have been studied extensively, it is still not comprehensively 
understood which retinal cells mediate the therapeutic effects of CNTF. As with therapeutic proteins 
in general, it is poorly elucidated whether exogenous CNTF administered into the vitreous can enter 
and distribute into the retina and hence reach potentially responsive target cells. Here, we have 
characterized our purified recombinant human CNTF (rhCNTF), studied the protein’s in vitro 
bioactivity in a cell-based assay, and evaluated the thermodynamic and oligomeric status of the 
protein during storage. Biological activity of rhCNTF was further evaluated in vivo in an animal 
model of retinal degeneration. The retinal penetration and distribution of rhCNTF after 24 h was 
studied utilizing two ex vivo retina models. Based on our characterization findings, our rhCNTF is 
correctly folded and biologically active. Moreover, based on initial screening and subsequent 
follow-up, we identified two buffers in which rhCNTF retains its stability during storage. Whereas 
rhCNTF did not show photoreceptor preservative effect or improve the function of photoreceptors 
in vivo, this could possibly be due to the used disease model or the short duration of action with a 
single intravitreal injection of rhCNTF. On the other hand, the lack of in vivo efficacy was shown to 
not be due to distribution limitations; permeation into the retina was observed in both retinal 
explant models as in 24 h rhCNTF penetrated the inner limiting membrane, and being mostly 
observed in the ganglion cell layer, distributed to different layers of the neural retina. As rhCNTF 
can reach deeper retinal layers, in general, having direct effects on resident CNTF-responsive target 
cells is plausible. 
Keywords: retinal penetration; neuroprotection; protein aggregation; stability; intravitreal delivery; 
CNTF 
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1. Introduction 
Progressive diseases of the posterior eye segment, and in particular those affecting the retina, 
are among the most common causes of visual impairment and blindness [1]. Cataract and glaucoma, 
for instance, are the two leading causes of blindness globally, whereas age-related macular 
degeneration (AMD) is the most common culprit for legal blindness in the aged population in high-
income countries, affecting approximately 10% of the population over 60 years of age [2,3]. 
Degenerative diseases of the posterior eye segment, including conditions such as diabetic retinopathy 
and retinitis pigmentosa (RP), are often age-related, and their prevalence is growing in the aging 
populations. 
Pharmaceuticals that target retinal disease pathogenesis are currently available only for the 
treatment of diabetic macular edema and the wet form of AMD, conditions that feature pathological 
angiogenesis in the retina, which is driven by the overexpression of pro-angiogenic factors [3]. 
Whereas other factors are involved, the vascular endothelial growth factors (VEGFs) are recognized 
as the main mediators responsible for the pathological neovascularization in the posterior eye 
segment [2]. Interfering with VEGFs’ binding to their receptors (VEGFRs) inhibits the VEGF-
triggered actions of these receptor tyrosine kinases. As such, VEGF-blocking as a treatment strategy 
is most commonly achieved with therapeutic proteins that bind and neutralize VEGF [1]. 
Although neovascular diseases result in retinal neurodegeneration in particular during 
advanced stages, anti-VEGF treatments rescue retinal neurons indirectly, and their ocular use is 
limited to treating neovascular diseases only. Effective treatments affecting retinal degeneration 
directly are still lacking [4]. As advanced posterior segment diseases in general feature degeneration 
and loss of retinal neurons, with photoreceptor loss ultimately accounting for the experienced loss of 
vision, targeting the involved pathways by means of direct neuroprotection is considered a more 
universal approach to combat retinal neurodegeneration [4,5]. Several growth factors and 
neurotrophic factors, e.g., brain-derived neurotrophic factor, fibroblast growth factors, glial cell-line 
derived factor, and nerve growth factor have been studied in preclinical animal models for their 
neuroprotective potential in oculo [6,7]. In addition to these, the ciliary neurotrophic factor (CNTF) 
is arguably the most studied and has progressed the furthest in clinical trials [4,8]. 
CNTF has an approximate molecular mass of 23 kDa and a four α-helix bundle tertiary structure 
[9,10]. It belongs to the interleukin-6 (IL-6) family of neuropoietic cytokines and exerts neurotrophic 
effects on a variety of neurons. Lacking a signal sequence for secretion, the mechanism by which 
CNTF gets released from cells is still unknown and postulated to occur upon cellular injury [8,11]. 
CNTF elicits its actions through a receptor complex consisting of the ligand-specific α-receptor 
CNTFRα, and β-receptors glycoprotein 130 (gp130) and leukemia inhibitory factor receptor β (LIFRβ) 
[9,11]. Lacking transmembrane and cytoplasmic domains, CNTFRα is anchored to the cell membrane 
by a glycosylphosphatidylinositol linker; cleavage of this linker can release soluble receptor, 
sCNTFRα, rendering cells expressing just gp130 and LIFRβ also capable of responding to CNTF [9]. 
In the retina, CNTF expression spans all layers and occurs in several cell types, such as retinal 
pigment epithelium (RPE), and particularly in glial cells such as astrocytes and Müller cells [8,12,13]. 
CNTF protein expression is upregulated in response to, e.g., stress and injury [12,14,15]. CNTFRα 
expressing retinal cells include astrocytes, Müller cells, retinal ganglion cells (RGC), rod and cone 
photoreceptors, and RPE [8,13,15–19]. Whereas both murine and rat central nervous system (CNS) 
microglia express CNTFRα [20–22], it is not fully clear whether local resident microglia do so in the 
retina, although they have nonetheless been shown to respond to CNTF [23]. 
Whereas CNTFRα expressing retinal cells are potentially responsive to CNTF, it is not 
established whether all of CNTF’s effects on different cell types are, in fact, direct or mediated 
indirectly by specific cells [8]. Observations on species differences in retinal CNTFRα expression in 
part complicate interpreting and extrapolating findings from one species to another [16]. 
Additionally, non-CNTFRα expressing retinal cells expressing the common signal transduction 
components could nonetheless be conferred responsive to CNTF by sCNTFRα [8,24]. Currently, 
CNTF’s neuroprotective effects on RGCs and photoreceptors are thought to take place (mostly) 
indirectly via Müller cells [8,12,25], which are postulated to respond to CNTF stimulation by 
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expressing and releasing other cytokines and neurotrophic factors that relay CNTF’s neuroprotective 
effects to other retinal cells [15,18,25–28]. 
Although the mechanisms and mediators of the biological effects of CNTF are still not fully 
resolved, its supportive and neuroprotective actions against retinal damage and degeneration have 
been demonstrated in various animal models of retinal disease [5,8]. The photoreceptor preservative 
effect related to upregulation of endogenous CNTF after mechanical or light-induced damage is well-
reported in literature [14,29,30], and multiple teams working on viral-mediated gene therapies or 
sustained release delivery systems have demonstrated the protective effects of CNTF in different 
animal models of retinal degeneration [31–36]. While intravitreally administered CNTF has been 
shown to protect photoreceptors from light-induced damage, the preservative effect on 
photoreceptor degeneration caused by a genetic defect has not been as clear and seems, to some 
extent, to depend on the species and disease model [36–39]. In S334ter-3 rats, intravitreal (IVT) 
injection of CNTF improved the retinal morphology, and especially the cone photoreceptors seemed 
to benefit from the treatment [35,40]. In a Royal College of Surgeons (RCS) rat, single subretinal 
injection of recombinant CNTF showed a long-term photoreceptor preservative effect up to 36 days 
[33]. However, the efficacy of intravitreally administered CNTF has not been previously studied in 
this animal model. 
Certain aspects of CNTF have been inadequately described in the literature. Whereas hCNTF 
variants with improved stability were in development for CNS delivery [41], publications reporting 
on the formulation and related stabilization efforts on CNTF are scarce. Previously, we reported on 
the optimized soluble expression and purification of our recombinant human CNTF (rhCNTF) [42]. 
Here, we describe further characterization and stability studies of rhCNTF. Although the Müller glia 
cells are considered the primary mediators of CNTF’s actions in the retina, direct effects on other cells 
cannot be ruled out as CNTF-responsive as well as CNTFRα-expressing cells have been identified in 
several retinal layers [8]. However, little is known about the retinal penetration and distribution of 
exogenously administered CNTF, although the inner limiting membrane (ILM) at the vitreoretinal 
interface has been postulated to be the biggest limitation to CNTF’s entry into the retina [27]. Here, 
we evaluate the efficacy of intravitreally administered rhCNTF in vivo in RCS rat and report on the 
retinal penetration and distribution of our rhCNTF in organotypic ex vivo retinal explant cultures. 
2. Materials and Methods 
2.1. Protein Production 
The features and construction of the expression plasmid pOPINF-hCNTF as well as the 
expression and purification of soluble recombinant His6-hCNTF, from now on referred to as rhCNTF, 
have been described earlier [42,43]. Aside from expression in RosettaTM 2(DE3)pLysS (Novagen, 
Merck KGaA, Darmstadt, Germany) E. coli cells using the Overnight Express™ Instant TB auto-
induction culture medium (Novagen, Merck) [44], rhCNTF was also expressed in the aforementioned 
cells using EnPresso® B growth system [45] (BioSilta Oy, Oulu, Finland) according to the 
manufacturer’s specifications. 
Protein purification was carried out as describer earlier [42] and is described in more detail in 
the Supplement. For further studies, the purified protein was kept on ice at 4 °C as well as snapfrozen 
with liquid N2 for storage at −80 °C. 
2.2. rhCNTF in Vitro Bioactivity Study 
The correct function, and thus indirectly the proper folding of purified rhCNTF, was 
demonstrated earlier in an enzyme-linked immunosorbent assay (ELISA) binding study with the 
cognate receptor CNTFRα [42]. To ensure that rhCNTF can trigger downstream signaling and hence 
biological responses, an in vitro cell study was performed. 
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2.2.1. Cell Culture 
TF-1-CN5a.1 (product CRL-2512™, American Type Culture Collection, ATCC®, Manassas, VA, 
USA) cells were obtained from LGC Standards (Teddington, UK). The cells were maintained in 
complete growth medium of Roswell Park Memorial Institute (RPMI) 1640 medium, 2 mM L-
glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate 
(RPMI-1640, ATCC modification; GibcoTM, Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (GibcoTM, Thermo Fisher Scientific), 2 ng/mL human 
granulocyte macrophage colony-stimulating factor (hGM-CSF) (Sigma-Aldrich, St. Louis, MO, USA), 
0.4 mg/mL G-418 (CalbiochemTM, Merck), and 100 U/mL penicillin – 100 µg/mL streptomycin 
(GibcoTM, Thermo Fisher Scientific). The cells were maintained as stationary suspension cultures in 
non-treated Nunc™ EasyFlask™ 75 cm2 flasks (Thermo Fisher Scientific) in a fully humidified 5% 
CO2 atmosphere at 37 °C. Cell number and viability were determined using trypan blue. 
2.2.2. Cell Proliferation Assay 
The bioactivity of the purified rhCNTF was verified by measuring cell proliferation in a 5-
bromo-2’-deoxyuridine (BrdU) incorporation assay [46], using the Cell Proliferation ELISA BrdU kit 
(Roche Diagnostics, Mannheim, Germany) according to manufacturer’s specifications. First, 50 µL of 
serial dilutions of purified rhCNTF in assay growth medium, i.e., complete growth medium without 
hGM-CSF and G-418, were prepared and added in triplicates to the wells of CELLSTAR® 96-well 
microplates for suspension cells (Greiner Bio-One GmbH, Kremsmünster, Austria). Cultured TF-
1.CN5a.1 cells were first centrifuged and washed with RPMI-1640 to remove hGM-CSF, followed by 
resuspension in assay growth medium. Cells were then seeded at 1.0 × 104 cells in 50 µL/well (final 
rhCNTF concentrations 24 fg/mL–100 ng/mL). Cells cultured in assay growth medium with and 
without 2 ng/mL hGM-CSF were used as positive and negative controls, respectively. Treated cells 
were incubated at 37 °C, 5% CO2 for 48 h. 
After incubation, 10 µL of 100 µM BrdU labeling solution was added to the wells and the cells 
(were) incubated for an additional 2 h, allowing for the incorporation of BrdU into the synthesized 
DNA during cell proliferation. After labeling, the suspended cells were pelleted by centrifugation at 
300 × g for 10 min, the media removed from the wells gently by pipetting, and the cells dried at 60 °C 
for 60 min. Then, 200 µL of FixDenat was added to each well for cell fixation and DNA denaturation 
and removed by pipetting after 30 min incubation at room temperature. Incubation with a 
peroxidase-conjugated anti-BrdU antibody was carried out for 90 min at room temperature to allow 
for binding to the incorporated and now exposed BrdU. Antibody solutions were then aspirated, and 
the cells were washed 4 times with 200 µL/well washing solution. After incubation with the 3,3′,5,5′-
tetramethylbenzidine substrate solution 15 min, the absorbances were determined at 370 nm and 492 
nm on a microplate reader (Varioskan® Flash; Thermo Fisher Scientific). 
2.3. rhCNTF Characterization and Stability Studies 
Upon visual inspection, we had observed precipitation—likely due to protein aggregation—
taking place upon freeze-thawing with previously purified rhCNTF stored in 100 mM NaH2PO4, 50 
mM NaCl, pH 8.0, 1 mM dithiothreitol (DTT) buffer at −80 °C resulting in a loss of approximately a 
third of stored protein (not shown). There was, hence, a clear need to find a more suitable storage 
buffer to stabilize the protein. 
To gain insight on the structure and stability of rhCNTF, the protein was subjected to 
experiments using circular dichroism, differential scanning fluorimetry, and dynamic light scattering 
to characterize, e.g., secondary structure, thermal unfolding, and oligomeric state. 
2.3.1. Circular Dichroism 
Circular Dichroism (CD) spectroscopy was utilized to study the secondary structure and folding 
of the purified rhCNTF. Far-UV CD spectra (190–260 nm) of rhCNTF (0.2 mg/mL) samples desalted 
with 5 mM phosphate buffer were obtained in a 0.1 cm quartz cuvette at 25 °C with a ChirascanTM-
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Plus CD Spectrometer (Applied Photophysics Ltd., Leatherhead, Surrey, UK). Background spectrum 
of the buffer was recorded and subtracted from subsequent triplicate spectral scans with the rhCNTF 
samples, with the average spectrum plotted. Pro-Data Viewer (Applied Photophysics) was used for 
data collection and handling. Data were normalized to protein concentrations and expressed in units 
of mean residue molar ellipticity. The BeStSel algorithm was also used for secondary structure 
determination from CD spectra [47]. 
Thermal denaturation and unfolding of rhCNTF was studied during thermal ramping from 25 
to 92 °C (1 °C/min) with far-UV CD (190–260 nm) measurements every 2 °C. Values for the onset 
(Tonset) and midpoint (Tm) of unfolding were determined by plotting measured ellipticity at 222 nm, a 
signal proportional to α-helical content, as a function of temperature. 
2.3.2. ThermoFluor 
Differential scanning fluorimetry, commonly known as ThermoFluor, is a thermal shift assay 
based on an increase in the fluorescence of several non-specific protein-binding dyes upon their 
binding to certain regions and residues that become accessible during protein unfolding [48,49]. From 
the recorded fluorescence signal, parameters such as the Th—the temperature of hydrophobic 
exposure—and other information of the thermal unfolding of proteins can be extracted. Here, based 
on observations that higher Th correlates with higher conformational stability in formulation, 
different conditions were tested for their effects on the Th of rhCNTF to screen for suitable buffers to 
stabilize the protein. 
Buffers were pipetted to semi-skirted qPCR 96-well plates (Agilent Technologies, Inc., Santa 
Clara, CA, USA) while rhCNTF protein samples and SYPRO® Orange (Thermo Fisher Scientific) were 
applied as droplets on opposing edges of the wells to prevent premature interactions. Wells were 
sealed with Bio-Seal 7 Transparent Adhesive Seals for PCR plates (BIOplastics, Landgraaf, The 
Netherlands), the plates were quickly centrifuged to bring all components together in a total reaction 
volume of 25 µL, mixed by gentle vortexing, and again centrifuged. The measurements were carried 
out in a Stratagene Mx3005P qPCR instrument (Agilent Technologies). Samples were heated from 25 
to 95 °C at a rate of 1 °C per 30 s. Fluorescence readouts were taken at every °C step using 492 nm 
and 610 nm as the excitation and emission wavelengths, respectively. Measurements were analyzed 
and Th values determined with MxPro qPCR software (Agilent Technologies). 
ThermoFluor was first carried out on a grid of varying rhCNTF and dye concentrations as a pre-
screening to optimize protein/dye concentrations [50], and the subsequent measurements carried out 
with the best match. To study the effects of buffer, ionic strength, and pH on rhCNTF thermostability, 
94 different conditions were screened for increased rhCNTF Th (Table S1). Arising trends in the Th as 
a surrogate for conformational stability were then followed with rhCNTF stored in chosen buffers at 
4 °C and −80 °C. 
2.3.3. Dynamic Light Scattering 
The formation and presence of protein aggregates was assessed using dynamic light scattering 
(DLS). DLS measurements were carried out using Zetasizer APS (Malvern Panalytical Ltd., Malvern, 
Worcestershire, UK) with a 830 nm laser source using the Zetasizer Software (Malvern Panalytical) 
for data acquisition and analysis. Purified rhCNTF samples in the chosen buffers were diluted to 1.0 
mg/mL and filtered using 0.22 µm polyethersulfone (PES) membrane filters to remove large 
particulates. Each sample was measured in triplicate at 2 °C. The size and hydrodynamic radius (Rh) 
distributions of detected particles were obtained by measuring and integrating the intensity of the 
scattered light, whereas for follow-up and comparing measurements, parameters were derived both 
via intensity and volume analysis. 
Samples kept on ice at 4 °C after purification as well as snap-frozen samples stored at −80 °C 
were measured at different time points to assess for changes and trends in the Rh. For the cryo-stored 
samples, measurements with thawed unmixed sample as well as with the supernatant from 
centrifuged (21,100 × g, 30 min at 4 °C) thawed rhCNTF were carried out for comparison. 
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The thermal aggregation behavior of rhCNTF was also studied with DLS by carrying out Rh 
measurements with freshly purified rhCNTF in both buffers during thermal ramping. To determine 
the onset temperature (Tagg), i.e., the temperature at which proteins start to associate and aggregate 
and at which scattering from HMW species intensifies, samples were heated from 2 to 60 °C and 
particle size measurements taken at each °C step. The measured Z-average (in nm) was plotted as a 
function of temperature. 
2.4. rhCNTF in Vivo Efficacy Study 
2.4.1. Animals 
The photoreceptor preservative effect of rhCNTF was assessed in vivo after an IVT bolus 
injection using Royal College of Surgeons (RCS) rat as an animal model of retinal degeneration. The 
animals were 18 or 21 days old, both male and female. Animals were kept in controlled conditions 
(12 h light/dark cycle, temperature 21 ± 2 °C, humidity 55 ± 15%, ventilation 15 times per hour), 
housed with a maximum of 5 animals per stainless-steel cage (28.5 cm × 48.5 cm × 20 cm) with food 
and water provided ad libitum. The cages were changed twice a week and provided with sufficient 
bedding, nesting material, and enrichment. All procedures were performed in accordance to the 
European and national legislation on the protection of animals used for scientific or educational 
purposes (Directive 2010/63/EU, Act 497/2013, Decree 564/2013; ESAVI/6791/04.10.07/2013). 
2.4.2. Intravitreal Injections 
Stock solution of rhCNTF protein in buffer M (100mM MES, 500 mM NaCl, pH 7.0) was thawed 
on ice prior to purification from aggregates by centrifuging (13 000 × g, 15 min, +2 °C, Heraeus Biofuge 
Fresco, Heraeus Instruments). The supernatant was diluted to 500 ng/mL with buffer M with 1 mM 
DTT, sterile filtered through 0.2 µm PTFE membrane (Acrodisc Syringe Filter CR13; PALL 
Corporation, Port Washington, NY, USA), stored in 4 °C, and used within one week. The final 
concentrations used for experiments were diluted with buffer M prior to injection from the stock 
solution. 
Animals were weighed and anaesthetized with intraperitoneal (i.p.) injection of 1 mg/kg of 
medetomidine (Domitor vet 1 mg/mL, Orion Corporation, Espoo, Finland) and 75 mg/kg of ketamine 
(Ketaminol vet 50 mg/mL, Intervet International B.V), diluted with 0.9% sodium chloride solution 
(Natriumklorid Braun, B.Braun, Germany). The pupils were dilated with tropicamide (Oftan 
Tropicamid 5 mg/mL, Santen Pharmaceutical Co., Ltd., Osaka, Japan), which was allowed to affect 
for 10 min to achieve full dilation of the pupils. Finally, carbomer eye gel (Viscotears, Novartis 
International GA, Basel, Switzerland) was added to the eyes to prevent corneal desiccation. 
In the 1st study set, 21-day-old animals received single IVT injection (2 µL) of 1 µg rhCNTF (n = 
4), 500 ng rhCNTF (n = 5) and 250 ng rhCNTF (n = 4) or buffer M (n = 4) into one eye, while the 
contralateral eye was left untreated and served as an internal control. 
In the 2nd study set, 18-day-old animals received single IVT injection (2 µL) of 1 µg rhCNTF (n 
= 7), or buffer M (n = 6) to one eye, while the contralateral eye was left untreated and served as an 
internal control. Untreated naïve control animals, NControl (n = 7) served as external control. 
Injection was performed with 5 µL Hamilton® syringe (Hamilton Company, Inc., Reno, NV, 
USA) using a sharp point 34-gauge needle. Incision was done approximately 1 mm from the limbus, 
at a 45-degree angle, towards the back of the vitreous. Eyes of the animals were treated with antibiotic 
ointment after injection (Dexamethasone 1 mg/g, chloramphenicol 2 mg/g, Oftan Dexa-Chlora, 
Santen Pharmaceutical Co.) to prevent inflammation and to minimize solution efflux from the 
vitreous. Anesthesia was reversed with i.p. injection of atipamezole (Antisedan vet 5 mg/mL, Orion 
Corporation.). The animals were monitored during anesthesia and recovery from procedure was 
ensured. Any animals with welfare issues, visible injuries to the injected eye, or other signs of 
unsuccessful operation were determined as outliers and eliminated from the experiment. 
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2.4.3. Electroretinogram (ERG) Recording 
Full-field ERG was recorded 1- and 2-weeks post-treatment. Animals were weighed and dark-
adapted overnight, for a minimum of 12 h. All procedures were carried out under dim red light. The 
animals were anesthetized, pupils dilated, and carbomer gel added to the eyes as previously 
described. The animals were placed on a heated surface during the measurements. Rod responses 
were stimulated in dark-adapted conditions with series of dim blue flashes with increasing intensities 
(0.003, 0.007, 0.03, and 0.5 cd × s/m2, number of sweeps 3, inter-sweep delay 5000 ms), whereas cone 
responses were stimulated under light-adapted conditions with series of bright white flashes (0.1, 1, 
3, 5, 10, and 20 cd × s/m2, number of sweeps 12, inter-sweep delay 0 ms) using ColorDome D125 
(Diagnosys LLC, Lowell, MA, USA). The retinal responses were detected from the cornea with 
custom-made circular golden electrodes and recorded using Espion Visual Electrophysiology System 
V6 (Diagnosys LLC). The resulting retinograms were analyzed using Espion V6 software. The 
recovery of the animals was monitored for two days after every recording. 
2.4.4. Data-Analysis 
ERG results were analyzed using non-parametric testing using Microsoft Excel, GraphPad Prism 
8, and IBM SPSS software. The parameter distribution between all treatment groups at all flash 
intensities was analyzed with the Kruskal–Wallis test. The comparison between the treated and 
untreated contralateral eye, as well as the comparison between the ERG values recorded 1 week and 
2 weeks post-injection, was achieved with the Wilcoxon signed-rank test. 
2.4.5. Histology 
Animals were euthanized at the age of 35 days (2nd study set) or 38 days (1st study set) with 
CO2 overdose followed by perfusion through the heart with 9% sodium chloride. The ocular tissue 
was pre-fixed in situ by perfusion through the heart by 4% paraformaldehyde (PFA) followed by 
ocular enucleation and fixation overnight in 4% PFA in 12-well plates in 4 °C. Thereafter, the eyes 
were rinsed in phosphate-buffered saline (PBS) for 2 to 6 h and dehydrated in the processing machine 
as described in Table S2 (Shandon Citadel 2000 Tissue Processor, Thermo Fisher Scientific). The eyes 
were embedded in liquid paraffin (64 °C), cooled to ambient temperature, and 5 µm vertical cross 
sections were cut close to the papilla (Leica SM2000R, Leica instruments GmbH, Germany or HM 
355S Rotary Microtome, Thermo Fisher Scientific). Sections were flattened on warm water bath and 
collected on microscope slides and treated with hematoxylin and eosin (H&E) staining procedure 
according to Table S3. Glass slides were covered with DPX plastic and allowed to dry for 18 to 30 h. 
Sections were imaged using a Zeiss light microscope (Axio Imager M2; Carl Zeiss AG, Oberkochen, 
Germany) with 20× magnification (EC Plan-NEOFLUAR 20X/0.5 objective, Carl Zeiss AG) using 
AxioCam MRm (Carl Zeiss AG). 
2.5. Retinal Penetration of rhCNTF 
2.5.1. rhCNTF Fluorescent Labeling 
Purified rhCNTF was fluorescently labeled with Alexa Fluor™ 488 Microscale Protein Labeling 
Kit (Thermo Fisher Scientific) via tetrafluorophenyl ester linkage to free amines according to 
manufacturer’s instructions. Unreacted dye was separated from labeled protein with provided spin 
filters and the degree of labeling analyzed with a DropSense16 spectrophotometer (Trinean NV, 
Gentbrugge, Belgium) according to manufacturer’s instructions, with a calculated degree of labeling 
(DOL) of 1.16 indicating the average number of dye molecules conjugated to each protein molecule. 
Labeled rhCNTF was aliquoted and stored on ice until use on rat retinal explant cultures. 
Similarly, rhCNTF was fluorescently labeled with NT-647 (NanoTemper Technologies, 
München, Germany) via N-hydroxysuccinimide ester linkage to free amines according to 
manufacturer’s instructions. Unreacted dye was removed with provided columns and the DOL 
analyzed with Varian Cary® 50 spectrophotometer (Agilent Technologies) according to 
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manufacturer’s instructions, with a calculated DOL of 0.557 indicating the average number of dye 
molecules conjugated to each protein molecule. Labeled rhCNTF was aliquoted and stored at −80 °C 
until use on bovine retinal explant cultures. 
2.5.2. Retinal Explant Culture Preparation and rhCNTF Treatment 
Rat retinal Explants 
Eyes obtained from CD® (SD) IGS rats were used to prepare organotypic retinal explant cultures 
as described earlier [51,52]. In brief, 5-, 6-, or 8-day-old animals were killed and the eyes enucleated 
in an aseptic environment. After cleansing with 70% ethanol, the eyes were incubated in basal R16 
medium (Invitrogen, Paisley, UK) for 5 min, followed by incubation in pre-warmed 0.12% proteinase 
K (MP BiomedicalsTM, Thermo Fisher Scientific) for 15 min at 37 °C. To inactivate proteinase K, the 
eyes were incubated in basal R16 medium containing 20% fetal bovine serum (Sigma-Aldrich) for 
5 min, and finally washed in serum-free basal R16 medium. Dissections were carried out aseptically 
in a Petri dish containing basal R16 medium. The anterior segment, sclera, choroid, lens, and the 
vitreous body were carefully removed, leaving only the retina together with the attached RPE. 
Finally, four relaxing cuts were made, and the retinae flat-mounted with the photoreceptor-side 
down on culture membrane inserts (0.4 µm; Corning Incorporated, Corning, NY, USA; 3412). 
Complete R16 medium was placed in the lower compartments of 6-well culture dishes, and the 
cultures were incubated at 36.5 °C and 5% CO2. No antibiotics or antimycotics were used. 
Explants were left without treatment for 24 h to allow them to adapt to culture conditions, 
followed by rhCNTF treatments for the next 24 h; the experiment duration was kept at a minimum 
to minimize explant deterioration, i.e., to retain the structure of all the retinal layers as close to native 
as possible. Alexa Fluor™ 488-labeled rhCNTF was prepared in PBS, diluted in basal R16 medium, 
and sterilized with 0.22 µM PES membrane filter before use. To mimic dosing via IVT and e.g., 
subretinal injections, treatments were given either apically as 15 µL drops (200 ng dose) carefully 
applied directly on top of the explant cultures or basolaterally as 4.7 µg/mL in complete medium 
below the explant in the lower compartment, respectively. Untreated complete R16 medium was 
used as control. 
Bovine Retinal Explants 
Retinal explant cultures were prepared as described earlier [53]. Fresh bovine eyes obtained from 
a local slaughterhouse were first cleaned off extra-ocular connective tissues followed by dipping in 
20% ethanol. The eye was bisected 10 mm below the limbus, the anterior segment discarded and the 
vitreous removed, with the remaining posterior eye cup filled with cold CO2 independent medium 
(Gibco™, Thermo Fisher Scientific) and cut into 4 flaps. While submerged in the medium, two circular 
pieces of the retina were isolated using a biopsy punch and then gently transferred onto moisturized 
75 mm Transwell® membrane with the photoreceptor-side down. Explant culture medium 
(Neurobasal™-A, 2% B-27™ supplement, 2% penicillin–streptomycin, 1% L-glutamine; all Gibco™, 
Thermo Fisher Scientific) was added below the insert and the explants incubated at 37 °C and 5% 
CO2. 
Treatments were given directly after explant preparation; 10 µL of NT-647-labeled rhCNTF (3 
µg dose) was applied gently on top of each explant, followed by incubation for 24 h at 37 °C. 
2.5.3. Tissue Culture Fixation and Sectioning 
Rat Retinal Explants 
Treated rat explants were fixed in 4% PFA (Polysciences, Inc., Warrington, PA, USA) at 4 °C for 
40 min. The fixative was then changed to 1% PFA and incubated at 4 °C overnight. Retinae were then 
washed with PBS for 10 min and cryoprotected by incubation in graded sucrose solutions (10%, 20%, 
and 30%). Subsequently, tissues were embedded in Tissue-Tek® O.C.T.™ Compound (Science 
Services GmbH, Munich, Germany). Vertical sections (14 µm) were obtained on a Leica CM3050S 
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Microtome (Leica Biosystems, Wetzlar, Germany), air-dried at 37 °C for 1 h, and stored at −20 °C until 
use. 
Bovine Retinal Explants 
Treated bovine explants were fixed by replacing the medium below the filter with 4% PFA (in 
PBS). After 2 h of incubation at 4 °C, PFA was discarded and replaced with 30% sucrose solution (in 
PBS) and incubated overnight at 4 °C. Explants were snap-frozen in Tissue-Tek® O.C.T Compound 
using liquid nitrogen and sections (16 µm) cut from four different region of the explant with cryostat 
(Leica CM3050s). 
2.5.4. Culture Staining and Imaging 
Rat Retinal Explants 
To prepare tissue sections from retinal explants for imaging, frozen cryosections were first air-
dried at 37 °C. Slides with fixed sections of retinal tissue were washed 3 times with PBS and then 
mounted in Vectashield® (Vector Laboratories, Inc., Burlingame, CA, USA). Immunofluorescence 
staining of the mounted sections was carried out as described in the Supplement. 
Mounted sections were imaged using a Zeiss Axio Imager Z1 ApoTome microscope equipped 
with a Zeiss AxioCam digital camera and AxioVision 4.7 software (all ZEISS). To observe the 
penetration of labeled rhCNTF, acquired images from multiple explant areas were assessed manually 
for the presence of fluorescence. 
Bovine Retinal Explants 
Sections from retinal explants were incubated for 1 h at room temperature in blocking solution 
(5% goat serum) followed by overnight incubation at 4 °C with rabbit anti-Collagen IV antibody 
(1:200) (Abcam plc., Cambridge, UK). Next, sections were stained with Alexa Fluor™ 488-labeled 
goat anti-rabbit secondary antibody (1:500) (Thermo Fisher Scientific) and 10 µg/mL Hoechst 33,342 
(Invitrogen™, Thermo Fisher Scientific) for 1 h at room temperature. 
Sections were mounted with Vectashield® (Vector Laboratories) and prepared for imaging. 
Sections were imaged with a Leica TCS SP8 confocal microscope using 20x (HC PL APO 20x/0.75 
IMM CORR CS2) and 93x (HC PL APO 93x/1.30 motCORR STED WHITE) objectives (all Leica 
Microsystems GmbH, Wetzlar, Germany). As before, the presence of fluorescence was assessed 
manually from multiple explant areas to observe penetration of labeled rhCNTF. 
3. Results 
3.1. Protein Production 
After expression, harvesting, and lysis, expressed rhCNTF was found mostly in the lysate 
supernatant, indicating soluble protein overexpression. The soluble protein was purified from the 
lysate with immobilized metal-ion affinity chromatography (IMAC), and the eluted fractions 
analyzed with SDS-PAGE (not shown). Fractions containing rhCNTF were pooled, concentrated, and 
subjected to SEC purification, with rhCNTF eluting from the column as a mostly solitary major peak 
at 56 mL (Figure 1), corresponding to an estimated molecular weight of approximately 26 kDa and in 
accordance with published literature and earlier SDS-PAGE analysis [42], with void volume 
aggregates and smaller oligomers eluted as distinct minor peaks and readily discarded (data not 
shown). Four separate batches of rhCNTF were purified in high purity, on average yielding 70 mg of 
protein per liter of culture. 
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Figure 1. Size-exclusion chromatography of IMAC-purified recombinant human ciliary neurotrophic 
factor (rhCNTF). Pooled and concentrated eluates from IMAC batch-purification were subjected to 
SEC in a Superdex 200 prep grade packed C16/40 column with 100 mM NaH2PO4, 300 mM NaCl, pH 
8.0, 1 mM DTT as the running buffer with a flow rate of 0.5 mL/min. The column was calibrated with 
blue dextran (A; 2,000 kDa), thyroglobulin (B; 669 kDa), apoferritin (C; 443 kDa), β-amylase (D; 200 
kDa), alcohol dehydrogenase (E; 150 kDa), bovine serum albumin (F; 66 kDa), carbonic anhydrase (G; 
29 kDa), and cytochrome c (H; 12.4 kDa). rhCNTF eluted at 56 mL (shown in red), with an estimated 
molecular weight of 26 kDa. 
3.2. rhCNTF in Vitro Bioactivity 
Aside from previously confirmed binding to the cognate receptor CNTFRα [42], the in vitro 
activity of purified rhCNTF was assessed based on the proliferation of TF-1.CN5a.1. The cell-line is 
engineered to stably express CNTFRα, and CNTF-mediated stimulation can hence support the short-
term proliferation of the cells. As illustrated in Figure 2, our purified rhCNTF supported the short-
term proliferation of the cells, observed via BrdU incorporation, in a dose-dependent manner. An 
approximate EC50 of 19 pg/mL (0.8 pM) was estimated for this effect, indicating that our purified 
rhCNTF was biologically active. 
 
Figure 2. 5-bromo-2’-deoxyuridine (BrdU) incorporation assay analysis of the in vitro biological 
activity of rhCNTF to support the proliferation of TF-1.CN5a.1 cells. rhCNTF supports the short-term 
proliferation of TF-1.CN5a.1 cells, with BrdU incorporation into synthesized DNA observed as a 
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proxy for cell proliferation. Each value shown as average mean of three biological replicates ± SD. 
Data were normalized to highest bioactivity of rhCNTF. 
3.3. Characterization and Stability of rhCNTF 
3.3.1. Circular Dichroism 
To investigate the secondary structure and folding of purified rhCNTF, far-UV CD analysis was 
carried out. In the recorded spectrum, an intense maximum around 190 nm with minima at 208 and 
220 nm were observed (Figure 3A), spectral features corresponding to a highly α-helical secondary 
structure [54]. The high estimated percentage of helicity (>50%), as obtained by spectral 
deconvolution with BeStSel, along with further comparison with published results, confirm the 
correct secondary structure and folding of purified rhCNTF [10,55–57]. Furthermore, CD analysis of 
the thermal denaturation of rhCNTF yielded a Tonset of 46 °C and a Tm of 53 °C (Figure 3B), in 
accordance with published literature [58]. 
(a)                                       (b) 
Figure 3. Far-UV circular dichroism analysis of rhCNTF. (a) Analysis of rhCNTF secondary structure 
at 25°C: characteristic maximum around 195 nm with minima at 208 and 220 nm point to a highly 
helical protein, reflecting the correct α-helical secondary structure and folding of purified rhCNTF. 
(b) Thermal denaturation of rhCNTF observed as changes in ellipticity at 222 nm, reporting α-helical 
unfolding. 
3.3.2. ThermoFluor 
First, a pre-screen was carried out to determine the optimal working concentrations of rhCNTF 
and SYPRO orange. The combination of 3.3 µM rhCNTF and 5X SYPRO Orange gave a maximal 
range of fluorescence and the best signal-to-noise ratio and was used for all subsequent 
measurements. 
We screened 94 different buffers (Table S1) for optimal thermal stability of the purified rhCNTF. 
In general, poor thermal stability was observed at low pH, with highest thermal stability observed in 
slightly acidic to neutral pH; the presence of salt was observed to both increase and decrease thermal 
stability, depending strongly on the buffering component (Table S4). Two buffers yielding clear 
fluorescence responses and high Th estimates were chosen for further use: 100 mM 2-(N-
morpholino)ethanesulfonic acid (MES), 500 mM NaCl, pH 7.0 (buffer M), and 100 mM sodium citrate, 
pH 5.6 (buffer C); both buffers were supplemented with 1 mM dithiothreitol (DTT) to prevent 
covalent dimer formation via free cysteines in rhCNTF monomers. To gain insight on rhCNTF’s 
stability during storage, ThermoFluor measurements were carried out with rhCNTF stored on ice at 
4 °C as well as at −80 °C in these buffers. As the observed Th showed only minor changes during the 
study, this was taken to reflect the retained conformational stability of rhCNTF (Figure 4A–C). 
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Furthermore, protein loss due to precipitation was not observed upon visual inspection of rhCNTF 
cryo-stored in these buffers (data not shown). 
 
Figure 4. Th estimation of rhCNTF during storage (a) on ice at 4 °C, (b) −80 °C, and (c) on ice at 4 °C 
post-thawing. 
3.3.3. Dynamic Light Scattering 
Hydrodynamic size estimation of rhCNTF was carried out with DLS. The mean estimated Rh of 
rhCNTF was 3.42 ± 0.50 nm and 2.95 ± 0.22 nm for protein stored on ice at 4 °C in buffers M and C, 
respectively (4 × 3 measurements). This peak likely reflects both monomeric and dimeric rhCNTF, as 
DLS often cannot distinguish between species of such similar sizes [59]. This peak had a slightly 
higher and more variable polydispersity index (PdI) of 0.06 ± 0.04 with rhCNTF stored in buffer M, 
whereas when stored in buffer C, the same peak was associated with a low PdI of 0.03 ± 0.01. 
The size and oligomeric state of rhCNTF were monitored by following changes in the Rh of the 
monomer/dimer peak and volume distribution percentage of high molecular weight (HMW) species 
during storage on ice at 4 °C (Figure 5A,B and Table S5) as well as at −80 °C (Figure 5C,D and Table 
S6). To examine whether centrifugation affected sample quality and detecting HMW species, a 
comparison was made between thawed and (a) unmixed vs. (b) centrifuged samples (Figure 5C,D, 
Tables S5 and S6). 
(a) (b)  
(c) 
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Figure 5. rhCNTF hydrodynamic radius estimates during storage on ice at 4 °C in a) buffer M, and b) 
buffer C, and at -80 °C in c) buffer M, and d) buffer C. Solid circles denote samples that were unmixed 
after thawing, and open circles denote centrifugally cleared thawed samples. Over time, more 
variations with the Rh of rhCNTF stored in buffer M were observed compared to only minor Rh 
variations with rhCNTF stored in buffer C. Each value shown as average mean ± SD (n = 3 technical 
replicates; one-way ANOVA, * p < 0.05, n.s. = no significance). 
During storage at 4 °C, statistically significant differences were not observed in the 
(monomer/dimer) peak Rh of rhCNTF stored in buffer C (Figure 5B,D), whereas when stored in buffer 
M, statistically significant changes in the peak Rh were observed (Figure 5A,C). By intensity 
distribution, HMW species below, in, and occasionally above the sub-visible range (100–1000 nm) 
were detected (Table S5). However, as the scattering intensity is proportional to the sixth power of 
the particle radius, when expressed in intensity distribution, the observed intensities and population 
percentages are disproportionately biased towards the HMW species relative to dominant smaller 
particles [59]. When instead expressed in volume distribution, the contribution of HMW populations 
is significantly reduced. As observed from the volume distribution, HMW species were absent in 
buffer C, and as this remained unchanged (Table S5), and the protein was concluded not to cluster 
into aggregates during storage at 4 °C. When stored at −80 °C, detected aggregates were likewise 
negligible (less than 0.1% of the total) or completely absent, and as removal by centrifugation had no 
effect, rhCNTF does not undergo aggregation during nor due to cryo-storage (Table S6). 
rhCNTF does, however, seem to undergo more aggregation in buffer M, as HMW particles were 
observed in both storage conditions also from volume distribution profiles/percentages, and as 
centrifugation was observed to influence the detection of aggregates (Tables S5 and S6). 
The onset of rhCNTF aggregation was studied during thermal ramping. Thermal aggregation of 
rhCNTF started at a Tagg of 38 °C in both buffers as determined with the proprietary multi-parameter 
analysis (Figure 6); in volume distribution analysis, HMW species appear at temperatures above 40 
°C. 
 
(a) (b) 
(c) (d) 
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Figure 6. Thermal aggregation curve of freshly purified rhCNTF. Aggregation of purified rhCNTF 
was measured by following the estimated Z-average (nm) with dynamic light scattering (DLS) as a 
function of temperature. Appearance of high molecular weight (HMW) species is observed at 
temperatures above 38 °C in both buffers. 
3.4. rhCNTF in Vivo Efficacy Study 
3.4.1. ERG: First Study Set 
Figure 7 presents individual scotopic ERG results for an animal in the 1 µg rhCNTF dosage 
group, one-week post-injection. The α and β wave amplitudes between the treated eye and the 
untreated contralateral eye do not substantially differ. Furthermore, the similarity of the graphs 
indicates equal visual capacity of the 1 µg rhCNTF treated and the untreated eye. 
 
Figure 7. Scotopic Electroretinogram (ERG) recorded one week after 1 µg rhCNTF injection to the left 
eye. Equal visual acuity between the rhCNTF-treated eye and the contralateral untreated eye (internal 
control) was observed. 
Figure 8 presents the recorded scotopic α and β wave amplitudes in different treatment groups 
one- and two-weeks post-injection (n = 3). Figure 9 presents the recorded photopic β wave value 
distribution at flash stimulus 1 cd × s/m2 (n = 3). No statistically significant differences could be seen 
in the scotopic α and β wave values or photopic β wave values between the treated and untreated 
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eyes in any treatment group at any flash intensity or timepoint (related samples Wilcoxon signed 
ranks test, significance level: p < 0.05). The differences in the parameter distribution across the 
different treatment groups were not statistically significant at any flash intensity in the scotopic or 
photopic ERG recorded 1 week or 2 weeks post-injection (Kruskal–Wallis test, significance level: p < 
0.05). The large range in the observed values indicates a large within-group variation in the test 
population. 
 
Figure 8. Scotopic α and β wave amplitudes one- and two-weeks post-injection. No statistically 
significant difference in the responses between any of the treatment groups could be detected. 
 
Figure 9. Photopic beta wave amplitudes at stimulus intensity 1 cd × s/m2 one- and two-weeks post-
injection. No statistically significant difference in the responses between any of the treatment groups 
at different timepoints could be detected. 
3.4.2. ERG: Second Study Set 
Mean values and standard error of the scotopic α and β wave amplitudes recorded one- and 
two-weeks post-injection are presented in Figure 10 (n = 6). Figure 11 presents the recorded photopic 
β wave value distribution at flash stimulus 1 cd × s/m2 (n = 6). Only in the highest scotopic ERG 
stimulus intensity recorded two weeks post-injection, a statistically significantly steeper α wave was 
observed in the 1 µg rhCNTF-treated eyes than in the contralateral untreated eyes, used as internal 
control (related samples Wilcoxon signed ranks test, significance level: p < 0.05, p = 0.043). No 
statistically significant differences could be seen in the scotopic α and β wave values or photopic β 
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wave values in other stimulus intensities or timepoints between the 1 µg rhCNTF-treated and internal 
control eyes. Comparison of the recorded scotopic α and β wave amplitudes in the 1 µg rhCNTF-
treated eyes between the two time points showed no significant change at any flash intensity, 
indicating no change in visual acuity over time (Figures S1 and S2) (related samples Wilcoxon signed 
ranks test, significance level: p < 0.05). A comparison of parameter distribution between the treatment 
groups showed no statistically significant differences in parameter distribution between the treated 
and control eyes (Figures S3–S5) (Kruskal–Wallis test, significance level: p < 0.05). 
R
e
s
p
o
n
s
e
 (
µ
V
)
 
Figure 10. Mean and SD of scotopic alpha and beta wave amplitudes one and two-weeks post-
injection. Scotopic 0.5 cd × s/m2 β wave amplitudes recorded one-week post-injection were 
significantly higher in the 2-(N-morpholino)ethanesulfonic acid (MES)-treated group than in 1 µg 
rhCNTF-treated group (Kruskal–Wallis test, p = 0.018) and NControl group (p = 0.025). However, the 
1 µg CNTF-treated group and the NControl group did not show any statistically significant difference 
between their mean values (p = 0.831) (n = 6). 
 
Figure 11. Mean and SD of photopic beta wave amplitudes at stimulus intensity 1 cd × s/m2 one and 
two-weeks post-injection. No statistically significant difference in the responses between any of the 
treatment groups at different time points could be detected (n = 6). 
3.4.3. Histology 
The effect of rhCNTF treatment on the morphology of the animals in the second study set was 
evaluated by the thickness and density of the outer nuclear layer (ONL) of the retina. Representative 
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histological samples prepared of MES (n = 2) NControl (n = 3) and 1 µg CNTF (n = 4) treated animals 
are presented in Figure 12. One animal in the 1 µg CNTF-treated group seemed to have denser and 
thicker ONL in the treated eye (A) than in the contralateral eye (B), however, this effect could not be 
seen in any other animals of the same treatment group. There was also variation in the progress of 
photoreceptor degeneration between individual animals at the same time-point. 
 
Figure 12. Effect of rhCNTF treatment on the morphology of the retina. Histological analysis of retinal 
sections did not show clear benefit of treatment with 1 µg rhCNTF (a) compared to internal control 
(b), Buffer M control (c), and Ncontrol (d). Scale bar 20 µm. INL, inner nuclear layer; ONL, outer 
nuclear layer. 
3.5. Retinal Penetration of Labeled rhCNTF 
In vivo, rhCNTF did not show any observable effect on photoreceptor function nor survival. 
Since this raised concerns on whether the IVT injected protein permeates the retina to reach CNTF-
responsive target cells, this was studied with fluorescently labeled rhCNTF in an ex vivo setting with 
retinal explants. 
In the rat retinal explants, fluorescence from labeled rhCNTF was observed mainly in the 
ganglion cell layer (GCL) but also deeper, for example in the inner nuclear layer (INL), 24 h after 
apical application, as illustrated in Figures 13A–E,G–K. No evident fluorescence from labeled 
rhCNTF was observed 24 h after basolateral application, as shown in Figure 13F,L. 
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Figure 13. rhCNTF penetration in rat retinal explants as visualized without (A–F) and with DAPI 
counterstaining (G–L). Alexa Fluor™ 488 labeled rhCNTF (green) penetrates and distributes in the 
retina after apical administration, with rhCNTF-positive cells observed in the neural retina in layers 
ranging from the GCL to the INL (A–E and G–K). No rhCNTF penetration is seen with basolaterally 
applied protein (F and L). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; 
RPE, retinal pigment epithelium. 
Since fluorescence from labeled rhCNTF was observed mostly in the GCL, and as retinal cells 
expressing CNTFRα include e.g., retinal ganglion cells and Müller glia in this layer, staining to 
visualize Iba-1 immunoreactivity was carried out to identify microglial cells. Upon closer inspection, 
rhCNTF was observed to co-localize with microglia in the rat explants, as illustrated in Figure 14. 
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Figure 14. rhCNTF co-localizes with microglia in the ganglion cell layer. Fluorescence from Alexa 
Fluor™ 488 labeled rhCNTF (green) co-localizes with Iba-1 immunopositivity (red). GCL, ganglion 
cell layer; INL, inner nuclear layer. 
24 h after apical application, fluorescence from the labeled rhCNTF was observed in most retinal 
layers in the bovine retinal explants, as shown in Figure 15 and Figure S6. Whereas fluorescence can 
be observed mostly at the ILM and GCL, rhCNTF-positivity is also observed in the outer plexiform 
layer (OPL) and the ONL. 
 
 
Figure 15. rhCNTF penetration in bovine retinal explant. NT-647 labeled rhCNTF (red) readily 
penetrates across inner limiting membrane (ILM) and distributes in the retina after apical 
administration, with evident fluorescence observed in the neural retina in layers ranging from 
ganglion cell layer (GCL) to outer plexiform layer (OPL). ILM, inner limiting membrane; GCL, 
ganglion cell layer; IPL, Inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer. 
4. Discussion 
Pharmacotherapeutic intervention affecting the disease mechanisms and causes is often limited 
to specific pathologies. For example, using anti-VEGF biologicals is restricted to treating posterior 
eye segment conditions featuring pathological neovascularization. Instead of blocking pathways 
ultimately leading to neurodegeneration, directly supporting the function and survival of neurons—
for example with different neurotrophic factors—is an attractive strategy to alter the course of 
pathology, and a potentially more universal approach in treating neurodegenerative diseases of 
diverse etiologies. The cytokine CNTF is of great interest as the protein’s neuroprotective effects on 
various retinal neurons have been demonstrated in numerous retinal disease models, subsequently 
ushering clinical evaluation in treating various retinal conditions in humans.  
In vitro bioactivity in a cell-based assay was used to verify the biological activity of purified 
rhCNTF by assessing its effects on the proliferation of a CNTF-responsive cell line. It is known that 
the lymphoblastoid cell line TF-1 responds to multiple cytokines, e.g., GM-CSF, IL-3, and 
erythropoietin by proliferating [60]. As TF-1 cells express IL-6Rα, another receptor subunit for CTNF 
[11], they can respond to exogenous CNTF. However, this binding is of markedly lower affinity 
compared to that with CNTFRα, resulting in a less pronounced proliferative response; simultaneous 
addition of soluble CNTFRα makes the TF-1 considerably more responsive to exogenous CNTF [61]. 
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To circumvent the need to add exogenous CNTFRα to cultured TF-1 cells, we used TF-1.CN5a.1, a 
TF-1 derived cell line transfected to stably express CNTFRα. The cells are thus capable of proliferating 
in response to much lower CNTF concentrations, and the cell line can be used to assess, e.g., the 
activity and potency of CNTF and its variants. Here, we demonstrated that aside from binding to its 
cognate receptor, our rhCNTF has the correct α-helical structure (Figure 3A) and is biologically active 
as it supported the short-term proliferation of TF-1.CN5a.1 cells with an estimated EC50 of 19 pg/mL 
(0.8 pM). 
4.1. Buffer screening and stability studies 
We investigated the stability of rhCNTF in various buffers. Although widely used in 
formulations for therapeutic proteins, sodium phosphate buffer has been reported to be unsuitable 
for the cryo-storage of many proteins, as the buffer undergoes so-called freeze acidification [62,63]. 
Particularly, the dibasic phosphate salt undergoes a selective crystallization process during cooling, 
leading to a decrease of up to 3 pH units during freezing [62,64]. Furthermore, low temperature, 
freeze-concentration of solutes, and the formation of ice-aqueous interfaces are but some examples 
of the physicochemical changes and potentially destabilizing stresses that proteins may experience 
during freezing [62]. Destabilization of the protein structure may lead to (partial) denaturation of the 
protein structure, and further to protein aggregation. Indeed, we observed major loss of purified 
protein when rhCNTF was stored in a sodium phosphate buffer at -80 °C. Thus, a more suitable buffer 
was required for the protein. 
Here, different buffer, salt, and pH conditions were screened with ThermoFluor to assess their 
effects on the conformational stability and Th of rhCNTF. Although high Th estimates were seen with 
several buffers, the observed fluorescence responses were low and the negative peaks in the first 
derivative plots were poorly discernible with certain buffers and the Th was therefore challenging to 
estimate reliably. Among the screened buffers, two with clear fluorescence responses and high Th 
estimates reflecting high thermal stability of rhCNTF (100 mM MES, 500 mM NaCl, pH 7.0, and 100 
mM sodium citrate, pH 5.6; both supplemented with 1 mM DTT) were chosen and further tested. 
Although the number of screened conditions is arguably limited, and as replications could 
admittedly reinforce our confidence in the obtained results, they, along with the DLS results, 
nonetheless provide information on suitable buffers that can serve as a basis of further formulation 
development for rhCNTF. Moreover, our results indicate useful starting points around which ‘fine’ 
screening, i.e., buffer optimization with different additives (e.g., glycerol, surfactants, polyols, and 
reducing agents) is advisable to further increase the stability of rhCNTF [65]. As the Th estimates 
remained fairly consistent during the follow-up measurements (Figure 4), despite being insufficient 
for rigorous statistical analysis, this led us to draw the conclusion that the conformational stability of 
our rhCNTF was retained during the study and in our experimental setup. 
Although thermal aggregation of rhCNTF initiates at temperatures above 38 °C in both buffers, 
this is not concomitant with heat-induced unfolding. As measured with CD and ThermoFluor, 
rhCNTF starts to unfold at temperatures above 46 °C (Tonset ; Figure 3B). The onset of aggregation at 
38 °C is, however, not necessarily due to association via exposed hydrophobic patches, as can be 
expected to occur later at higher temperatures. Further elucidation is warranted to gain a more 
comprehensive understanding of the protein’s aggregation behavior. Moreover, upon 
administration, the protein gets exposed to the vastly different, complex, and potentially hostile in 
vivo environment that has been postulated to influence the formation and nature of aggregates 
[66,67]. Therefore, as the Tagg is close to normal body temperature, it cannot be ruled out that rhCNTF 
could not undergo aggregation to some degree in oculo after administration at 35 °C in the vitreous. 
Although engineered CNTF variants with improved chemical and physical properties were 
originally developed for CNS delivery [41], it would be of interest to investigate whether they are 
more stable in the eye as well. 
Particle sizing results suggest that oligomerization of rhCNTF differs in the two buffers. Overall, 
the slightly larger Rh estimate with rhCNTF in buffer M is likely due to the composition of the solvent. 
The presence of high salt concentration – in this case, 500 mM NaCl – can shield the charge-mediated 
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protein-protein repulsive forces, decreasing the diffusivity of macromolecules in solution and 
appearing as an increase in measured hydrodynamic size [68,69]. When stored in this buffer, 
appearance of HMW species is detectable, whereas no dramatic oligomerization takes place in buffer 
C in either storage condition (Tables S3 and S4). In intensity distributions, HMW particles were 
detected in both buffers, but when expressed in volume distribution, larger particles were evident 
only in buffer M (Table S4). Although based on volume distribution profiles, the amount of HMW 
species is negligible in buffer C; further development of a therapeutic rhCNTF lead molecule and its 
formulation may still require additional engineering and optimization to prevent the formation of 
even trace aggregates detected only in intensity distributions here. 
Even though DLS is a powerful method for the detection and rate determination of oligomer 
and larger aggregate formation, the underlying mechanism(s) of aggregation cannot be determined 
with this method. Our studies were not set up for uncovering whether trace oligomers and HMW 
aggregates present in storage and induced during thermal ramping are irreversible, covalent, 
insoluble, etc., and this would require further studies with orthogonal methods, such as SEC with 
multi-angle laser light scattering (MALLS), analytical ultracentrifugation (AUC), and nanoparticle 
tracking analysis (NTA) [70,71]. Such studies could also yield results to corroborate the findings 
presented here. Lastly, although not feasible during our study, we realize that assessing rhCNTF’s 
binding to CNTFRα and/or effect on cell proliferation during our stability studies could provide even 
more concrete proof of the stability and retention of rhCNTF function during storage. 
Finally, the intraocular stability of therapeutic proteins is of immense importance; even though 
the eye is often considered an immune-privileged site, it is possible that therapeutic protein 
aggregates in the vitreous would induce immune responses [67] that could affect the efficacy and 
safety of these drugs. Studies on therapeutic protein stability, aggregation, and immunogenicity after 
intravitreal administration are still, however, scarce. Although not studied here, in situ stability 
concerns are equally pertinent with IVT CNTF, warranting further investigations that could, for 
example, be carried out by adopting recently described ex vivo approaches [72,73] to study these 
aspects with rhCNTF. 
4.2. In vivo bioactivity of rhCNTF 
Based on the results from the first study set, the rhCNTF treatment did not have a dose-
dependent positive or negative effect on the recorded ERG values, and the photoreceptors in the 
rhCNTF-treated eyes did not seem to benefit from the treatment compared to the control eyes. As 
there was no significant reduction in the photoreceptor function over time, it is possible that the 
photoreceptor degeneration did not progress dramatically between the recordings, or that the 
photoreceptor degeneration was already rather extensive in the animals aged 28 days, when the ERG 
was recorded for the first time. Therefore, in the second study set, the animals were treated at an 
earlier time point, around the onset of photoreceptor degeneration. In the second study set, the group 
treated with 1 µg rhCNTF was the only group that showed no significant reduction in the scotopic 
ERG values over time; however, this finding alone was not substantial enough to prove any 
therapeutic effect of CNTF treatment on photoreceptor degeneration. 
While ERG has proven to be an effective method in evaluation of retinal function in RCS rats, it 
appears that the reduction of the ERG response might not always correlate well with the anatomical 
loss of photoreceptors [74]. There has also been some scientific debate whether CNTF is, in fact, 
detrimental to the rod photoreceptors as in some in vivo studies intraocular CNTF therapy has 
paradoxically reduced the scotopic ERG responses. A dose-dependent transient reduction in ERG 
responses has been observed in normal Long-Evans rats after IVT injection of CNTF that 
corresponded with a morphological reduction in ROS length with full recovery observed by three 
weeks post-injection [75]. Multiple teams using viral-mediated gene therapy have also reported 
diminished ERG amplitudes in treatment groups or no observable improvement in ERG, whilst the 
number of preserved photoreceptors has been higher in treatment groups [18,31,32,76]. Some teams, 
however, have been able to improve the scotopic or photopic ERG values with viral CNTF treatments 
or CNTF secreting devices in different animal models [33,35,36,40]. There is evidence that CNTF can 
Pharmaceutics 2020, 12, 611 22 of 31 
 
reduce the rhodopsin levels and other proteins important in the phototransduction cascade [25]. 
Therefore, the photoreceptor preservative effect of CNTF could be counteracted by the negative effect 
it presents on the functionality of the preserved photoreceptor in the retina. However, in our 
experiments, rhCNTF did not affect the retinal morphology, nor the function. 
RCS rat has a mutation in the gene encoding tyrosine kinase receptor Mer, affecting the ability 
of RPE cells to phagocytise rod outer segment (ROS) debris [74,77,78]. With time, the ROS debris 
accumulates, eventually forming a layer between the RPE cells and photoreceptors, leading to 
gradual photoreceptor degeneration and full blindness by the age of two to three months [74]. The 
gradual decrease in the scotopic ERG responses in RCS rats is presented in Figure 16. Even though 
CNTF related photoreceptor preservative effect has been observed in RCS rat [14,30,33], it is possible 
that halting the rapid progression of photoreceptor generation in this animal model is challenging 
with a single bolus injection of therapeutic protein, making sustained delivery systems more feasible 
options. 
 
Figure 16. Scotopic 0.5 cd x s/m2 ERG of Royal College of Surgeons (RCS) control animal at the age of 
10 months, RCS dystrophic rat at the age of 24 days, 30 days, and 9 weeks. The progressive 
photoreceptor degeneration and loss of photoreceptor functionality can be seen as the α and β wave 
(marked as a and b in the graph) amplitudes decrease in magnitude rather rapidly between 24 and 30 
days in the RCS dystrophic rat, whilst the 10-month old RCS control animal exhibits distinct α and β 
wave responses. The fully blind nine-week-old RCS dystrophy rat has no measurable α or β wave 
amplitudes. 
The pharmacokinetics (PK) of CNTF have so far been studied in rats only with systemic CNTF, 
reporting a short systemic half-life of 2.9 min; when discussing the ocular PK of CNTF, the 1994 
papers by Dittrich et al. [79] and Sendtner et al. [80] and subsequent publications citing these are 
commonly referred to. Although the early papers discuss the PK of systemically administered CNTF 
in rats, in the citing literature the results are often straightforwardly extrapolated to represent the in 
vivo PK of CNTF in general, and it has been assumed that CNTF would lose its therapeutic effect 
quickly also in the vitreous after IVT injection due to rapid clearance [36,81]. Regrettably, claiming 
the ocular half-life of CNTF to be in the same time-scale—of mere minutes—as in the circulation, is a 
gross and lamentable misinterpretation of the publications’ results. 
Studies on the intravitreal pharmacokinetics of macromolecules carried out in rabbits have 
shown that macromolecules can have a half-life of several days, and that the half-life of the 
macromolecule in the vitreous is greatly dependent on the intravitreal clearance, which in turn is 
small for those macromolecules that cannot pass the BRB, as is thought to be the case with CNTF 
[6,82]. Biologicals are eliminated from the vitreous predominantly via the anterior route [83], with 
the hydrodynamic size considered as the major determinant in the ocular half-life of a given 
biological [84,85]. Although experimental data on the vitreal half-life of CNTF is as of writing scarcely 
published, in a study with rat CNTF injected in mouse vitreous—although owing to practical 
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limitations the vitreal CNTF levels were not assessed with total retinal levels reported instead [17]—
we doubt that the levels would be as high as reported if the protein truly had a rapid vitreal 
elimination. Based on hydrodynamic radius estimations presented here, the calculated intravitreal 
half-life of rhCNTF are 4.67 days (Rh 2.95 nm) and 4.96 days (Rh 3.32 nm) (see Supplement), estimates 
that do not differ drastically from experimentally determined half-lives of other IVT administered 
macromolecules [86–88] and definitely not in the order of minutes. Even so, the vitreal half-life of 
CNTF is nevertheless finite and sustained intraocular release, and retinal delivery of CNTF has been 
explored utilizing various strategies: for example, an intravitreally injected hydrogel [58], cell-based 
systems [89], and several gene therapy approaches [18,90–94]. The most clinically advanced, 
Renexus® (NT-501; Neurotech Pharmaceuticals, Inc., Cumberland, RI, USA) is an implant with 
encapsulated, genetically engineered ARPE-19 cells, that secrete and maintain low concentrations of 
human CNTF in the vitreous over several years [19]. Its neuroprotective effects have been evaluated 
in patients with dry AMD [95,96], CNGB3-achromatopsia [97], glaucoma [98], retinitis pigmentosa 
[5,19,99], and macular telangiectasia type 2 (MacTel 2) [100]. No efficacy was evident in CNGB3-
achromatopsia patients [97], and only moderate efficacy was observed in RP patients and patients 
with geographic atrophy secondary to dry AMD [95,96]. However, after some therapeutic efficacy 
was observed in a recent phase 2 study in MacTel 2 patients [100], two phase 3 studies are now 
recruiting patients for evaluating the safety and efficacy of Renexus® in treating MacTel 2 
(NCT03316300, NCT03319849), whereas the results of a recent phase 2 study in glaucoma patients 
(NCT02862938) are currently expected. 
4.3. Retinal penetration and effects of rhCNTF 
As no apparent neuroprotective effects were observed with IVT administered rhCNTF in vivo, 
in case this was related to the protein’s ability to permeate into the retina, the postulated target cells 
were evaluated. Here, we demonstrate that after apical administration, our labeled rhCNTF—a small 
(26 kDa) protein—permeates into the neural retina in both explant models in 24 h. Consistent with 
findings with intravitreally administered antibody fragments [101], crossing the RPE was not 
observed with basolaterally applied rhCNTF as the protein did not permeate to the neural retina. 
Given that the half-lives of intravitreally administered protein therapeutics are in the range of 
several days [102], we realize that in this context, the time scale of the given rhCNTF treatments is 
short. However, we chose to limit the treatments to 24 h in order to ensure the structural and 
physiological integrity of the explants, and on the other hand, that the stability of the protein–
fluorophore conjugates was also retained during the experiments. Whilst not studied with the rat 
explants, and although based on collagen staining, the ILM appears intact in our experiments with 
the bovine explant (Figure 15 and Figure S6), adapting a recently described bovine explant model 
developed to ensure the integrity of the ILM and vitreoretinal interface [53] could be used to 
complement our findings, and to further define the contribution of these primary barriers in the 
retinal permeation of biologicals in general. It should also be noted that as the ILM in the rodent eye 
is poorly representative of human physiology compared to larger species, information obtained with 
bovine models may better reflect the in vivo situation in the human eye [53,101]. Even though the 
ILM is considered the primary barrier to retinal entry from the vitreous [53], e.g., the size-cutoffs 
remain undetermined [83], whereas the porosity of the ILM meshwork in human and animal eyes is 
still not fully clear [103]. Likewise, how recognized species differences relate to the applicability of 
different animals’ eyes in evaluating the retinal penetration of vastly different particles remains to be 
comprehensively elucidated. Whilst reports on the retinal permeation of biomacromolecules is by 
and large qualitative with sparse truly quantitative estimates published [83], as several full-sized 
mAbs [86–88] and even large particles such as nanocarriers have nonetheless been reported to 
penetrate into the retina [103], the ILM could, in fact, be an insignificant barrier to the retinal entry of 
biologicals, and in particular small proteins as seen with rhCNTF here. 
As our retinal penetration experiments were not set up for studying the neuroprotective effects 
of our rhCNTF, conclusions thereof cannot be drawn here. Nonetheless, as labeled rhCNTF 
penetrated the ILM and permeated to retinal layers with CNTFRα-expressing cells, our results 
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indicate that CNTF’s availability to the target cells should not be a limitation for its direct effects in 
the retina. Although published results suggest that the retinal microglia respond to CNTF in rats [23] 
and our labeled rhCNTF did indeed co-localize with local microglia in the GCL, it is not clear if these 
cells express CNTFRα and whether they are responsive to CNTF directly or indirectly. Therefore, 
verifying the microglial expression of the cognate receptor is pertinent to further corroborate our 
findings. The experiments could straightforwardly be expanded to assess the activation of the 
identified downstream signaling pathways of CNTF, such as JAK/STAT3, ras-MAPK, and PI3K/AKT 
[11,23]. Similarly, since the neurotrophic effects of CNTF are in part mediated by glial cells in the eye, 
mass spectrometry for example could be utilized to analyze microglial expression and secretion of 
other growth factors in response to stimulation with rhCNTF. Lastly, application of conditioned 
medium of microglial cells treated with rhCNTF to retinal explants and explant models of retinal 
degeneration and pathologies may also be carried out to assess e.g., protection of photoreceptors as 
well as to investigate the stimulation and secretory responses of Müller glia. 
Although the bovine explants are viable only for a short duration [53], rodent explants can in 
comparison be maintained in culture for several weeks; explants exhibiting retinal pathologies and 
degeneration can also be induced, or, as eyes from preclinical animal disease models are available, 
prepared thereof [51,104]. As aging and diseases can affect the structures and the integrity of drug 
delivery barriers such as the BRB and the ILM [83,105], we see such rodent explant models potentially 
applicable in comparing how such changes in the retinal physiology influence the retinal permeation 
and distribution of protein therapeutics. In order to ensure that meaningful information is extracted 
in such studies, it is obviously essential to confirm that the explants retain their physiological integrity 
and truthfully reflect the physiological situation [106]. 
Even though the relevance of the retinal permeation of protein therapeutics is underlined in 
several publications [88,103,107,108], it is still an incompletely understood area of the intravitreal 
pharmacokinetics thereof. Aside from presented studies with rhCNTF, we envision the retinal 
explant models utilized in studying the retinal penetration and distribution of various other proteins 
of therapeutic interest, e.g., mAbs, Fab fragments, and Fc-fusion proteins. In particular, the explants 
could prove invaluable in systematically elucidating how different factors, such as protein 
hydrodynamic radius, charge, and FcRn-binding act as determinants in this regard. As it is possible 
that protein therapeutics with differing characteristics permeate into the retina at different rates, 
study designs naturally require robustness. On one hand, it has been proposed that retinal 
penetration might not be a universal requisite with all modalities [83]. On the other hand, there is 
support for opposing views; although current anti-VEGF therapeutics have extracellular targets, their 
permeation into the retina to bind free retinal VEGF is necessary for maximal VEGF inhibition based 
on a recent in silico study [109]. Even though posterior clearance is considered to play only a minor 
role in the vitreal clearance of protein therapeutics, it is indeed unclear whether penetrating into the 
retina interplays with the pharmacological effects of protein therapeutics in vivo. It is thus of great 
importance to investigate how retinal permeation of proteins, especially with different modes of 
action, is connected to their therapeutic efficacies in the eye and whether this can be influenced by 
protein engineering for example. Such studies could potentially provide explanations on why many 
proteins developed for ocular conditions have failed in clinical trials. Ultimately, they might offer 
valuable clues on overcoming recognized ocular barriers and thus help in bringing novel treatments 
to the clinic. Here, utilizing both in vivo as well as ex vivo methods, such as the described retinal 
explants, are essential [105]. 
5. Conclusions 
Here, we focused first on verifying the bioactivity of rhCNTF, and subsequently on the 
characterization and stability studies of the protein. Whereas the protein’s activity was demonstrated 
in an in vitro cell proliferation assay, screening identified buffers in which the physicochemical 
stability of rhCNTF was retained during storage, providing a basis for further rhCNTF development 
and formulation efforts. Even though here rhCNTF showed no photoreceptor preservative effects in 
vivo, using ex vivo organotypic retinal explants we demonstrated, to the best of our knowledge, for 
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the first time the permeation of labeled rhCNTF to the neural retina and additionally the exogenous 
cytokine’s co-localization with outer retinal macrophages. Whilst the lack of in vivo effects could, for 
example, be due to the extent of degeneration in the used disease model or the limited duration of 
action achievable with a single bolus injection, as the cytokine was observed to distribute to the neural 
retina, we conclude that this was not due to rhCNTF failing to reach responsive cells. 
As the factors affecting retinal penetration of protein therapeutics are still unclear, there is a need 
for methods with which such information can be acquired. To improve the knowledge in this area, 
further studies are clearly necessary. As such, complementing the in vivo and in silico work carried 
out and described in recent literature, we hope our findings give impetus to—among other 
applications—explore the further use of retinal explant models to systematically elucidate the retinal 
permeation of protein therapeutics. 
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